Effect of carni Q-gel (ubiquinol and carnitine) on cytokines in patients with heart failure in the TISHCON study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN89073451

Enrollment

Registered

2007-03-30

Start date

2005-09-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Heart Failure Circulatory System Heart failure

Interventions

Nine carni Q-gel softgels (three with each meal thrice daily), which provide a total of 270 mg ubiquinol and 2250 mg L-carnitine daily, or nine matching placebos were administerd to each patient, duri

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Both men and women affected by Chronic Heart Failure (CHF) of mixed etiology 2. Ischaemic, hypertensive, valvular heart disease and idiopathic dilated cardiomyopathy 3. Severity of disease was assessed by New York Heart Association (NYHA) functional Class II to IV

Exclusion criteria

Exclusion criteria: 1. Hypertrophic cardiomyopathy 2. Amyloid cardiomyopathy 3. Not willing to give consent 4. Patients presenting with shock 5. Chronic renal failure 6. Cancer

Design outcomes

Primary

Measure	Time frame
1. Increase in distance walked in six minutes 2. NYHA class of heart failure 3. Echocardiographic cardiac size	—

Secondary

Measure	Time frame
Reduction in TNF-alpha and IL-6	—

Countries

India

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026